Company: SXTPW
Filing Date: 2025-01-28
Form Type: 8-K
Source: 0001213900-25-007529
Chunk: 0

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-01-28
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

On January 28, 2025, 60 Degrees Pharmaceuticals,
Inc. (the “ Company”) issued a press release announcing the approval of an Investigational Review Board (IRB) sanctioned Phase
II clinical study. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.

The information set forth under this Item 8.01,
including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific
reference in such a filing.

Item 9.01 Financial Statements and Exhibits.